Please use this identifier to cite or link to this item:
|Title:||High-dose intravenous immunoglobulin is effective diabetic polyneuropathy resistant to conventional treatments. Results of a double-blind, randomized, placebo-controlled trial: comments||Authors:||Wee, TC
|Issue Date:||20-Mar-2020||Abstract:||We read with interest a recent publication by Jann et al., “High-Dose Intravenous Immunoglobulin Is Effective Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled Trial” . The results suggest intravenous immunoglobulin (IVIG) as a promising pain treatment modality for this group of patients. Although the study methodology has provided a detailed outline of its population recruitment, there was no information regarding the severity of diabetes and diabetic control, in terms of micro- and macrovascular complications and HbA1c levels. Better glycemic control is known to reduce the incidence of clinical neuropathy, although its impact on pain is unknown . Nevertheless, improvement in diabetic control during the course of the study remains a potential confounder and may have an influence on the symptoms of DPN.||URI:||http://hdl.handle.net/11055/1022||DOI:||10.1093/pm/pnaa057||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/32196108||ISSN:||1526-2375||Journal Title:||Pain Medicine||Type:||Journal Article||Affiliates:||Changi General Hospital
Singapore General Hospital
|Appears in Collections:||Scholarly and Clinical|
Show full item record
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.